Location of Repository

Stability of the core domain of p53: insights from computer simulations

By Arumugam Madhumalar, Derek John Smith and Chandra Verma
Topics: Proceedings
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2259418
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (2007). A consensus view of protein dynamics.
    2. (2002). AJ: Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor.
    3. (2000). AJ: Surfing the p53 network. Nature
    4. (1998). Allatom empirical potential for molecular modeling and dynamics studies of proteins.
    5. (2005). Attempts to delineate the relative contributions of changes in hydrophobicity and packing to changes in stability of ribonuclease S mutants. Biochemistry
    6. (1993). Blundell TL: Comparative protein modelling by satisfaction of spatial restraints.
    7. (1999). BW: Structural analysis of a non-contiguous second-site revertant in T4 lysozyme shows that increasing the rigidity of a protein can enhance its stability.
    8. (2001). BW: Structural and thermodynamic analysis of the binding of solvent at internal sites in T4 lysozyme. Protein Sci
    9. (1997). Caput D: Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell
    10. (2005). Characterization of the denaturation of human alpha-lactalbumin in urea by molecular dynamics simulations. Proteins
    11. (2006). CN: Hydrogen bonding increases packing density in the protein interior. Proteins
    12. (2000). Collective protein dynamics in relation to function. Curr Opin Struct Biol
    13. (2006). Comparison of the human and worm p53 structures suggests a way for enhancing stability. Biochemistry
    14. (1992). Conjugate Peak Refinement: an algorithm for finding reaction paths and accurate transition states in systems with many degrees of freedom.
    15. (2002). DR: Large and Fast Relaxations inside a protein: Calculation and Measurement of Reorganisation Energies in Alcohol Dehydrogenase.
    16. (2006). Effect of Zn2+ ions on DNA recognition and stability of the p53 DNA-Binding Domain. Biochemistry
    17. (1999). Ellington AD: In vitro evolution of thermostable p53 variants. Protein Sci
    18. (1998). F: p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, deathinducing, and dominant-negative activities. Mol Cell
    19. (2002). Factors governing loss and rescue of DNA binding upon single and double mutations in the p53 core domain. Nucleic Acids Res
    20. (1996). Fersht A: Structural and energetic responses to cavity-creating mutations in hydrophobic cores: observation of a buried water molecule and the hydrophilic nature of such hydrophobic cavities. Biochemistry
    21. (2002). Fersht AR: A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci
    22. (2004). Fersht AR: Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations.
    23. (2006). Fersht AR: Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains.
    24. (2006). Fersht AR: Effects of oncogenic mutations and DNA response elements on the bindingBMC Bioinformatics 2008, 9(Suppl 1):S17 http://www.biomedcentral.com/1471-2105/9/S1/S17
    25. (2000). Fersht AR: Mechanism of rescue of common p53 cancer mutations by secondsite suppressor mutations.
    26. (2000). Fersht AR: Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene
    27. (2007). Fersht AR: Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex. Proc Natl Acad Sci USA
    28. (1998). Fersht AR: Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability.
    29. (2006). Fersht AR: Solution structure of p53 core domain: structural basis for its instability. Proc Natl Acad Sci USA
    30. (2006). Fersht AR: Structural basis for understanding oncogenic p53 mutations and designing rescue drugs.
    31. (2004). Fersht AR: Structural distortion of p53 by the mutation R249S and its rescue by designed peptide: implications for "mutant conformation".
    32. (2007). Fersht AR: Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene
    33. (2005). Fersht AR: Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations.
    34. (1984). Haak JR: Molecular dynamics with coupling to an external bath.
    35. (2001). High thermostability and lack of cooperative DNA binding distinguish the p63 core domain from the homologous tumor suppressor p53.
    36. (1993). HJ: Essential dynamics of proteins. Proteins
    37. (2007). Improved sampling methods for molecular simulation. Curr Opin Struct Biol
    38. (1999). Lane DP: Molecular evolution of the thermosensitive PAb1620 epitope of human p53 by DNA shuffling.
    39. (2007). Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol
    40. (2002). Live or let die: the cell's response to p53. Nat Rev Cancer
    41. (1993). LJ: Particle mesh Ewald: An N. log(N) method for Ewald sums in large systems.
    42. (2003). Loh SN: Structure, function, and aggregation of the zinc free form of he p53 DNA binding domain. Biochemistry
    43. (2000). Metalloregulation of the tumor suppressor protein p53: Zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and intact cells. Oncogene
    44. (1998). Modulation of p53 protein conformation and DNA-binding activity by intracellular chelation of zinc. Mol carcinog
    45. (1996). New insights into p53 function from structural studies. Oncogene
    46. P: Structural aspects of the p53 protein in relation to gene evolution: a second look.
    47. (1994). Pavletich NP: Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations. Science
    48. (2006). Prives C: Mutational analysis of the p53 Core Domain L1 loop.
    49. (2007). Prives C: p53 and p73 display common and distinct requirements for sequence specific binding to DNA. Nucleic Acids Res
    50. (2005). Protein stability and ligand binding: new paradigms from in-silico experiments. Biophys Chem
    51. Roberts CK: Calculation of the Reaction Pathway for the Aromatic Ring Flip in Methotrexate Complexed to Dihydrofolate Reductase.
    52. (1995). Role of cysteine residues in regulation of p53 function. Mol Cell Biol
    53. (1998). Rotation of structural water inside a protein: calculation of the rate and vibrational entropy of activation.
    54. (2002). Selivanova G: Restoration of the tumor suppressor function to mutant p53 by a low-molecularweight compound. Nat Med
    55. (2006). Shakked Z: Structural basis of DNA recognition by p53 tetramers. Mol cell
    56. (2006). Similarity trap" in protein-protein interactions could be carcinogenic: simulations of
    57. (2007). SM: Structural rigidity of a large cavity-containing protein revealed by high-pressure crystallography.
    58. (2006). Structure of the p53 core domain dimer bound to DNA.
    59. (2005). The Amber biomolecular simulation programs.
    60. (2003). The Development of a QM/MM Based Linear Response Method and its Application to Proteins. In
    61. (2002). The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat
    62. (1998). The PyMOL Molecular Graphics System.". DeLano Scientific LLC:
    63. (2006). Theory and simulation: Accuracy and reliability in modeling protein and complexes. Current Opin Struct Biol
    64. (2007). Thirumalai D: Allosteric transitions in the chaperonin GroEL are captured by a dominant normal mode that is most robust to sequence variations.
    65. (2007). Thorough validation of protein normal mode analysis: a comparative study with essential dynamics. Structure
    66. (1994). TJ: CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res
    67. (2005). Vousden KH: Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer cell
    68. (2004). WE: Replacement of staphylococcal nuclease hydrophobic core residues with those from thermophilic homologues indicates packing is improved in some thermostable proteins.
    69. (1997). WG: p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.